Treatment Regimen
Table 5B. FDA Approved Lipid Modulating Combination Tablets Drug Class, Agents and Daily Doses
Extended-release niacin/lovastatina Advicor ® 500/20 to 2000/80 mg/day
LDL-C 34-47% HDL-C 24-33% TG 35-48% ApoB (LDL-P) ≤ 40%b
Extended-release niacin/simvastatincd, e Simcor ® 500/20 to 2000/40 mg/day
LDL-C 34-56% HDL-C 15-29% TG 22-38% ApoB (LDL-P) ≤ 50%
Lipid/Lipoprotein Effects (varies with dosage used) Side Effects
Myopathy Flushing Hyperglycemia & Hyperuricemia Hepatotoxicity
Myopathy Flushing Hyperglycemia & Hyperuricemia Liver enzyme elevations
Ezetimibe/simvastatinf Vytorin ® 10/10 to 10/80 mg/day
Amlodipine/atorvastatin Caduet ® 2.5/10 to 10/80
LDL-C 45-60% HDL-C 6-10% TG 23-31% ApoB (LDL-P) ≤ 50%g
LDL-C 18-55% LDL particle number 18-55% HDL-C 5-15% TG 7-30%
a Advicor Prescribing Information, Abbott Laboratories, North Chicago, IL. b
c Simcor Prescribing Information, Abbott Laboratories, North Chicago, IL. d
e
Myopathy Liver enzyme elevations
Headache Edema Myopathy Liver enzyme elevations
Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended- release/lovastatin with s Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667-672.
Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet o cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101(10):1428-1436.
Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the efficacy and safety of a combination tablet o study. J Clin Lipidology. 2008;2:79-90.
f Vytorin Prescribing Information, Merck/Schering-Plough Pharmaceuticals, North Wales, PA. g Catapano AL, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercho
